

## **Hematology and Medical Oncology Leadership Transition**

**Message from Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute**

After serving as Chief of the Division of Hematology and Medical Oncology since 2009, System Chief for the Division since 2014, and Deputy Director of The Tisch Cancer Institute (TCI) since 2017, Dr. William Oh has decided to step down from these roles, effective December 31, 2020. Dr. Matthew Galsky will assume the role of Acting Chief of the Division for the Mount Sinai Health System, effective January 1, 2021. There will be a national search to identify the permanent division chief.

Dr. Oh will continue his patient care practice at The Mount Sinai Hospital, treating patients with genitourinary cancers, with a focus on prostate cancer. Additionally, he will assume a new position as Chief Medical Science Officer with [Sema4](#), a patient-centered health intelligence company and Mount Sinai Venture. Dr. Oh has previously served as Chair of Sema4's Scientific Advisory Board for Oncology.

As Chief of the Division of Hematology and Medical Oncology, Dr. Oh developed a highly-regarded program that has helped elevate TCI's reputation. He transformed the division through the recruitment of dozens of young, talented faculty as well as faculty of established renown, who are setting standards for excellence in cancer care. Expanding on TCI's hematologic malignancies service, Dr. Oh built a robust solid tumor service that ensures a full complement of cancer care for The Mount Sinai Health System. He also elevated the fellowship program into one that attracts accomplished trainees with tremendous promise who enhance our clinical and translational research activities. Under Dr. Oh's leadership, the division experienced an impressive record of grant awards, with a doubling from 22 million to 44 million in the last 5 years.

As Deputy Director of TCI, Dr. Oh was instrumental in the successful 2020 renewal of TCI's National Cancer Institute Cancer Center Support Grant. As longtime Chair of the Clinical Research Steering Committee for TCI, he established and oversaw clinical trials infrastructure and developed our new Clinical Cancer Investigation Program, advancing our platform for novel and innovative therapies.

We are indebted to Dr. Oh for his highly effective and inspiring leadership and accomplishments.

Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer, Director of the Early Phase Trial Unit, Co-Leader of the Cancer Clinical Investigation Program, and Associate Director for Translational Research at TCI. Since joining Mount Sinai in 2010, Dr. Galsky has built two major clinical research programs—in genitourinary cancers and early phase therapeutics—that have become among the highest accruing clinical trial programs at TCI. He personifies compassionate patient care, scientific collaboration, and mentoring of junior faculty and trainees. I am confident that he will guide the Division of Hematology and Medical Oncology with forward-thinking and thoughtful leadership.